11 results about "Streptococcus pneumoniae bacteria" patented technology

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

This invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular glycoantigens (glycoconjugates) and their uses. The immunogenic compositions of this invention will generally comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. This invention also relates to the use of said novel immunogenic compositions for the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

The present invention relates to new vaccine formulations comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Vaccine formulations of the invention typically comprise at least one glycoconjugate from an S. pneumoniae serotype in a formulation designed to facilitate resuspension. [Figure 1] TIFF2025541706000005.tif58160

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The present application relates to the field of ophthalmic drugs, and particularly relates to an ophthalmic composition, a preparation method and application thereof, the ophthalmic composition comprising a compound as shown in formula I, an osmotic pressure regulator, a pH regulator and water for injection; the pH value of the ophthalmic composition is 4.0-6.0; the concentration of the compound as shown in formula I is 0.1-3.0% w / v, and the concentration of the osmotic pressure regulator is 0.3-10.0% w / v; the antibacterial activity against Streptococcus pneumoniae, Staphylococcus aureus and Staphylococcus epidermidis is 2-8 times that of levofloxacin and moxifloxacin hydrochloride; the antibacterial activity against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli and Pseudomonas aeruginosa is also strong, and is equivalent to that of levofloxacin and moxifloxacin hydrochloride; the irritation is small, the light stability and high-temperature stability are good, the quality and drug safety are guaranteed, and the application value is good.

The application discloses an antibacterial peptide, a preparation method thereof and application of the antibacterial peptide in preparation of a preparation for treating pneumonia, and belongs to the technical field of biological medicines. The antibacterial peptide is a mutant of endolysin derived from a gram-negative bacteriophage. The bacteriophage endolysin plays an antibacterial / killing effect by degrading bacterial cell walls, and basically does not produce drug resistance. Common pneumonia pathogenic bacteria, i.e., Moraxella catarrhalis, Streptococcus pneumoniae and Staphylococcus aureus, are used as indicator bacteria, three antibacterial peptide mutants EAMP-M1, EAMP-M2 and EAMP-M3 with better antibacterial effects are screened, experiments prove that the three antibacterial peptide mutants have better antibacterial effects on gram-positive bacteria and gram-negative bacteria, can be applied to prevention, treatment or auxiliary antibiotic treatment of common pneumonia infection, and can be used in the field of medical instruments, such as sterilization of surgical instruments, and have a wide and good market application prospect.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.